P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
Study context
- Population
- Acute coronary syndromes (ACS) patients undergoing percutaneous coronary intervention (PCI) with latest-generation drug-eluting stents (DES), randomised after successful PCI and up to 4 days after admissionplanned enrolment
- Participants
- 3,400 patients
- Planned comparison
- Single antiplatelet therapy (SAPT) with a potent P2Y12 inhibitor vs dual antiplatelet therapy (DAPT)
- Primary endpoint
- Non-inferiority for all-cause mortality, stroke, MI or urgent target vessel revascularisation; superiority for BARC 2, 3 or 5 bleeding
- Follow-up
- 12 months
Methodological detailsrationale and design, multicentre, open-label, blinded outcome assessment, non-inferiority, Choice between ticagrelor and prasugrel at investigator's discretion
- Rationale and design
- Multicentre
- Open-label
- Blinded outcome assessment
- Non-inferiority
- Choice between ticagrelor and prasugrel at investigator's discretion
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. EuroIntervention. Published 17 July 2023. doi:10.
Summarised from the published abstract; every number is checked against it